LKLauri Koivula

Lauri Koivula

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lauri Koivula has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Juha Korhonen

    Medical Imaging and Radiation Therapy, Kymenlaakso Central Hospital, Kotka, FINLAND

    4 shared publications
  • Juhani Collan

    Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4 Building 2, 00290 Helsinki, Finland

    3 shared publications
  • Tiina Seppälä

    Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4 Building 2, 00290 Helsinki, Finland

    3 shared publications
  • Mika Kapanen

    A Cancer Centre, Helsinki University Hospital , Helsinki , Finland

    2 shared publications
  • Adalsteinn Gunnlaugsson

    Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden

    1 shared publication
  • Antje-Christin Knopf

    Department of Radiation Oncology, University Medical Center Groningen, Groningen, NETHERLANDS

    1 shared publication

Latest Publications

  • Open Access

    Feasibility of MRI-only photon and proton dose calculations for pediatric patients with abdominal tumors

    by Filipa Guerreiro, Lauri Koivula, Enrica Seravalli, Geert O Janssens, John H Maduro, Charlotte L Brouwer, Erik W Korevaar, Antje-Christin Knopf, Juha Korhonen, Bas W Raaymakers

    The purpose of this study was to develop a method enabling synthetic computed tomography (sCT) generation of the whole abdomen using magnetic resonance imaging (MRI) scans of pediatric patients with abdominal tumors. The proposed method relies on an automatic atlas-based segmentation of bone and lungs followed by an MRI intensity to synthetic Hounsfield unit conversion. Separate conversion algorithms were used for bone, lungs and soft-tissue. Rigidly registered CT and T2-weighted MR images of 30 patients in treatment position and with the same field of view were used for the evaluation of the atlas and the conversion algorithms. The dose calculation accuracy of the generated sCTs was verified for volumetric modulated arc therapy (VMAT) and pencil beam scanning (PBS). VMAT and PBS plans were robust optimized on an internal target volume (ITV) against a patient set-up uncertainty of 5 mm. Average differences between CT and sCT dose calculations for the ITV V 95% were 0.5% (min 0.0%; max 5.0%) and 0.0% (min −0.1%; max 0.1%) for VMAT and PBS dose distributions, respectively. Average differences for the mean dose to the organs at risk were <0.2% (min −0.6%; max 1.2%) and <0.2% (min −2.0%; max 2.6%) for VMAT and PBS dose distributions, respectively. Results show that MRI-only photon and proton dose calculations are feasible for children with abdominal tumors.


  • MRI-only based radiation therapy of prostate cancer: workflow and early clinical experience

    by Mikko Tenhunen, Juha Korhonen, Mika Kapanen, Tiina Seppälä, Lauri Koivula, Juhani Collan, Kauko Saarilahti, Harri Visapää

    Background: Magnetic resonance imaging (MRI) is the most comprehensive imaging modality for radiation therapy (RT) target delineation of most soft tissue tumors including prostate cancer. We have earlier presented step by step the MRI-only based workflow for RT planning and image guidance for localized prostate cancer. In this study we present early clinical experiences of MRI-only based planning. Material and methods: We have analyzed the technical planning workflow of the first 200 patients having received MRI-only planned radiation therapy for localized prostate cancer in Helsinki University Hospital Cancer center. Early prostate specific antigen (PSA) results were analyzed from n = 125 MRI-only patients (n = 25 RT only, n = 100 hormone treatment + RT) and were compared with the corresponding computed tomography (CT) planned patient group. Results: Technically the MRI-only planning procedure was suitable for 92% of the patients, only 8% of the patients required supplemental CT imaging. Early PSA response in the MRI-only planned group showed similar treatment results compared with the CT planned group and with an equal toxicity level. Conclusion: Based on this retrospective study, MRI-only planning procedure is an effective and safe way to perform RT for localized prostate cancer. It is suitable for the majority of the patients.


  • Intensity-based dual model method for generation of synthetic CT images from standard T2-weighted MR images – Generalized technique for four different MR scanners

    by Lauri Koivula, Mika Kapanen, Tiina Seppälä, Juhani Collan, Jason A. Dowling, Peter B. Greer, Christian Gustafsson, Adalsteinn Gunnlaugsson, Lars E. Olsson, Leonard Wee, et al.


  • Open Access

    Feasibility of MRI-only treatment planning for proton therapy in brain and prostate cancers: Dose calculation accuracy in substitute CT images

    by Lauri Koivula, Leonard Wee, Juha Korhonen

    Purpose: Magnetic resonance imaging (MRI) is increasingly used for radiotherapy target delineation, image guidance, and treatment response monitoring. Recent studies have shown that an entire external x-ray radiotherapy treatment planning (RTP) workflow for brain tumor or prostate cancer patients based only on MRI reference images is feasible. This study aims to show that a MRI-only based RTP workflow is also feasible for proton beam therapy plans generated in MRI-based substitute computed tomography (sCT) images of the head and the pelvis. Methods: The sCTs were constructed for ten prostate cancer and ten brain tumor patients primarily by transforming the intensity values of in-phase MR images to Hounsfield units (HUs) with a dual model HU conversion technique to enable heterogeneous tissue representation. HU conversion models for the pelvis were adopted from previous studies, further extended in this study also for head MRI by generating anatomical site-specific conversion models (a new training data set of ten other brain patients). This study also evaluated two other types of simplified sCT: dual bulk density (for bone and water) and homogeneous (water only). For every clinical case, intensity modulated proton therapy (IMPT) plans robustly optimized in standard planning CTs were calculated in sCT for evaluation, and vice versa. Overall dose agreement was evaluated using dose–volume histogram parameters and 3D gamma criteria. Results: In heterogeneous sCTs, the mean absolute errors in HUs were 34 (soft tissues: 13, bones: 92) and 42 (soft tissues: 9, bones: 97) in the head and in the pelvis, respectively. The maximum absolute dose differences relative to CT in the brain tumor clinical target volume (CTV) were 1.4% for heterogeneous sCT, 1.8% for dual bulk sCT, and 8.9% for homogenous sCT. The corresponding maximum differences in the prostate CTV were 0.6%, 1.2%, and 3.6%, respectively. The percentages of dose points in the head and pelvis passing 1% and 1 mm gamma index criteria were over 91%, 85%, and 38% with heterogeneous, dual bulk, and homogeneous sCTs, respectively. There were no significant changes to gamma index pass rates for IMPT plans first optimized in CT and then calculated in heterogeneous sCT versus IMPT plans first optimized in heterogeneous sCT and then calculated on standard CT. Conclusions: This study demonstrates that proton therapy dose calculations on heterogeneous sCTs are in good agreement with plans generated with standard planning CT. An MRI-only based RTP workflow is feasible in IMPT for brain tumors and prostate cancers.